Virtually all cases of mantle cell lymphoma (MCL) carry the t(11;14)(q13;q32) translocation, leading to the juxtaposition of the CCND1/CYCLIND1 gene to the immunoglobulin heavy chain (IGH) joining region, resulting in cyclin D1 mRNA and protein overexpression. [1] [2] [3] The existence of "true" MCL negative for cyclin D1 has been controversial but was recently substantiated by gene expression profiling. 4 Fu et al reported 6 cases of cyclin D1-negative lymphomas with pathologic and clinical features otherwise typical of MCL, and a molecular signature similar to that of cyclin D1-positive MCL. In these cyclin D1-negative MCL, the tumor cells overexpressed instead either cyclin D2 or cyclin D3, but had no evidence of chromosomal aberration involving the corresponding CCND2 and CCND3 genetic loci. Subsequently, 2 additional cases of cyclin D1-negative/cyclin D2-positive MCL were reported to harbor a t(2;12)(p11;p13) fusing the CCND2 gene to the IGK locus. 5 Here, we report a case of cyclin D1-negative MCL with strong nuclear expression of cyclin D2 and a cryptic t(12;14)(p13; q32), juxtaposing the CCND2 gene next to the IGH locus. This lymphoma occurred in a 52-year-old man with stage IV disease involving the bone marrow and gastrointestinal tract. The diagnostic lymph node biopsy showed morphologic and immunopheno-typic features typical of MCL (CD20 ϩ , CD5 ϩ , CD10 Ϫ , CD23 Ϫ , CD43 ϩ , BCL-2 ϩ , BCL-6 Ϫ ), except for lack of cyclin D1 expression ( Figure 1A-E) . Conversely, most nuclei were positive for cyclin D2 ( Figure 1F ) and by competitive real-time- Hybridization of spread metaphases with LSI IGH Dual Color, Break Apart Rearrangement probe (Vysis) shows one chromosome 14 with a normal hybridization pattern (juxtaposed centromeric orange and telomeric green probes) and one chromosome 14 hybridizing only with the centromeric probe, indicating an IGH break (arrow); loss of the telomeric part of the probe precluded identification of the partner chromosome (G). A break apart FISH assay for CCND2 locus rearrangement (telomeric BAC clone: RP11-578L13; centromeric BAC clone: RP11-388F6) shows 2 chromosomes 12 with a normal hybridization pattern and hybridization of the telomeric green probe to 14q, indicating a cryptic t(12;14)(p13:q32) (H). The CCND2 rearrangement is confirmed in the lymph node sample by interphase FISH as the nuclei show 2 yellow (normal chromosomes 12) and one or 2 green (derivative 14) signals with the 2 BAC clones (I). H&E and immunostains images were visualized under a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan) equipped with Nikon Plan Fluor 10ϫ, 20ϫ/0.50 NA, 40ϫ/ objective lenses and a CFW-1310C camera (Scion, Frederick, MD); images were acquired using Histolab 5.131.1 (Alphelys, Plaisir, France) and processed using Adobe Photoshop v7.0. FISH images were acquired with a 100ϫ immersion objective with an Olympus BX51 fluorescence microscope equipped with the appropriate filter sets, and were documented and processed using the FISH cytovision software. Figure 1G ). Because of apparent cyclin D2 overexpression, the tumor cells were investigated for a CCND2 rearrangement, using a break apart FISH assay as previously described. 4 A break in the CCND2 locus was clearly demonstrated, with the telomeric probe mapping to 14q32 ( Figure 1H ). The short arms of both chromosomes 12 were normal, demonstrating a derivative 14 through a cryptic t(12; 14)(p13;q32) translocation. Interphase FISH confirmed a CCND2 rearrangement in the lymph node ( Figure 1I ). This is the first description of a cyclin D1-negative MCL with a t(12;14)(p13;q32) and cyclin D2 overexpression. Of the 4 cyclin D1-negative/cyclin D2-positive MCL previously reported, 2 were found to harbor a genetic alteration of the CCND2 gene, due to a translocation to the IGK locus. 4, 5 Our findings in the current case confirm that CCND2 is recurrently targeted by chromosomal rearrangements in cyclin D1-negative MCL, and identify IGH as a previously undescribed translocation partner. By analogy to other translocations involved in B-cell lymphomas, one would have expected to find this translocation more often. Interestingly, the t(12;14)(p13;q32) translocation has, to date, not been described. This is likely due to the rarity of true cyclin D1-negative MCL with CCND2 alterations but also to the cryptic nature of this rearrangement.
Systematic FISH investigation of suspected cyclin D1-negative MCL overexpressing cyclin D2 without obvious 12p13 and/or 14q32 rearrangements might lead to the identification of additional cases harboring this hitherto unrecognized translocation. 
To the editor:
Peripheral blood blast clearance during induction therapy in acute myeloid leukemia Elliott and colleagues have reported in a group of 73 patients with acute myeloid leukemia (AML) that the time to clearance of peripheral blood blasts (PBB) during standard induction therapy is a strong predictor of both overall (OS) and relapsefree survival (RFS). 1 We have previously shown 2 in 30 AML patients that the kinetics of PBB clearance is a predictor of complete remission (CR). Thus, the 2 studies have in common the objective to obtain the maximum predictive information from the analysis of peripheral blood (ie, a much less invasive procedure than bone marrow aspiration); however, their results differ in several respects.
(1) The study reported by Elliott et al was retrospective whereas ours was prospective. (2) Elliott et al assumed that PBB clearance is a surrogate of in vivo chemosensitivity, but their study was carried out only on responder patients whose leukemic cells are, by definition, at least sufficiently chemosensitive for the patients to achieve CR; our study, instead, was carried out on unselected consecutive patients. (3) In the study by Elliott et al, PBB clearance was evaluated by differential count; in our study we identified by flow cytometry for each patient at the time of diagnosis a population of leukemic cells with aberrant immunophenotype (LAIP), and then determined absolute LAIP-positive blast counts on each of the first 5 days of treatment. Approval was obtained from Careggi Hospital institutional review board for this study. Informed consent was obtained in accordance with the Declaration of Helsinki.
By our approach (having doubled our series 2 to 61 patients), we have observed from day 2 (ie, within 24 hours from starting therapy) a clear dichotomy between responders and nonresponders ( Figure 1A) : indeed, the difference between the medians in the 2 groups is statistically significant from day 2. CR took place in 31 of 41 (76%) patients who had a reduction greater than 2 logs on day 5; but in only 1 of 20 (5%) patients who had a lesser reduction.
Unlike Elliott et al, in our series we do not yet have long-term follow-up data. However, because we found that peripheral blood LAIP-positive cell clearance correlates with bone marrow LAIPpositive residual disease (LD14: see Figure 1B) , and residual disease in turn is known to correlate with RFS, [3] [4] [5] it is reasonable to assume that PBB clearance will correlate with RFS. Thus, the combined data provided by Elliott et al and by our study demonstrate that from peripheral blood analysis it is possible to obtain strong predictors of both CR and RFS: in this respect the 2 studies are complementary. We concur
